{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T08:30:33Z","timestamp":1750926633535},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00059-023-05168-4","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T14:04:34Z","timestamp":1682431474000},"page":"206-211","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["RAAS inhibition and beyond\u2014cardiovascular medications in patients at risk of or affected by COVID-19","RAAS-Hemmung und dar\u00fcber hinaus\u00a0\u2013 Herz-Kreislauf-Medikation bei Patienten mit einem Risiko f\u00fcr oder Erkrankung durch COVID-19"],"prefix":"10.1007","volume":"48","author":[{"given":"Alexander","family":"Dutsch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heribert","family":"Schunkert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"key":"5168_CR1","unstructured":"WHO (2023) Coronavirus disease (COVID-19) pandemic dashboard. https:\/\/covid19.who.int\/. Accessed: 27.01.2023"},{"key":"5168_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann\u00a0M, Kleine-Weber\u00a0H, Schroeder\u00a0S et al (2020) SARS-coV\u20112 cell entry depends on ACE2 and TMPRSS2 and is blocked by a\u00a0clinically proven protease inhibitor. Cell 181:271\u2013280.e8","journal-title":"Cell"},{"key":"5168_CR3","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm1267","volume":"11","author":"K Kuba","year":"2005","unstructured":"Kuba\u00a0K, Imai\u00a0Y, Rao\u00a0S et al (2005) A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 11:875\u2013879","journal-title":"Nat Med"},{"key":"5168_CR4","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/cvr\/cvaa078","volume":"116","author":"L Chen","year":"2020","unstructured":"Chen\u00a0L, Li\u00a0X, Chen\u00a0M et al (2020) The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV\u20112. Cardiovasc Res 116:1097\u20131100","journal-title":"Cardiovasc Res"},{"key":"5168_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1161\/01.RES.0000205761.22353.5f","volume":"98","author":"U Danilczyk","year":"2006","unstructured":"Danilczyk\u00a0U, Penninger\u00a0JM (2006) Angiotensin-converting enzyme II in the heart and the kidney. Circ Res 98:463\u2013471","journal-title":"Circ Res"},{"key":"5168_CR6","first-page":"F62","volume":"235","author":"AJ Naftilan","year":"1978","unstructured":"Naftilan\u00a0AJ, Oparil\u00a0S (1978) Inhibition of renin release from rat kidney slices by the angiotensins. Am J Physiol 235:F62\u201368","journal-title":"Am J Physiol"},{"key":"5168_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1042\/CS20171550","volume":"133","author":"AM South","year":"2019","unstructured":"South\u00a0AM, Shaltout\u00a0HA, Washburn\u00a0LK et al (2019) Fetal programming and the angiotensin-(1\u20137) axis: a\u00a0review of the experimental and clinical data. Clin Sci (Lond) 133:55\u201374","journal-title":"Clin Sci (Lond)"},{"key":"5168_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.amjcard.2006.01.059","volume":"98","author":"CM Ferrario","year":"2006","unstructured":"Ferrario\u00a0CM, Strawn\u00a0WB (2006) Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 98:121\u2013128","journal-title":"Am J Cardiol"},{"key":"5168_CR9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.taap.2010.02.009","volume":"245","author":"SX Han","year":"2010","unstructured":"Han\u00a0SX, He\u00a0GM, Wang\u00a0T et al (2010) Losartan attenuates chronic cigarette smoke exposure-induced pulmonary arterial hypertension in rats: possible involvement of angiotensin-converting enzyme\u20112. Toxicol Appl Pharmacol 245:100\u2013107","journal-title":"Toxicol Appl Pharmacol"},{"key":"5168_CR10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1113\/expphysiol.2007.041855","volume":"93","author":"I Hamming","year":"2008","unstructured":"Hamming\u00a0I, van Goor\u00a0H, Turner\u00a0AJ et al (2008) Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats. Exp Physiol 93:631\u2013638","journal-title":"Exp Physiol"},{"key":"5168_CR11","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/cid\/ciaa329","volume":"71","author":"TC Hanff","year":"2020","unstructured":"Hanff\u00a0TC, Harhay\u00a0MO, Brown\u00a0TS et al (2020) Is there an association between COVID-19 mortality and the renin-angiotensin system? A call for epidemiologic investigations. Clin Infect Dis 71:870\u2013874","journal-title":"Clin Infect Dis"},{"key":"5168_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00059-020-04920-4","volume":"45","author":"T Kessler","year":"2020","unstructured":"Kessler\u00a0T, Schunkert\u00a0H (2020) Inhibitors of the renin-angiotensin system and SARS-CoV\u20112 infection. Herz 45:323\u2013324","journal-title":"Herz"},{"key":"5168_CR13","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou\u00a0F, Yu\u00a0T, Du\u00a0R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a\u00a0retrospective cohort study. Lancet 395:1054\u20131062","journal-title":"Lancet"},{"key":"5168_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/HJH.0b013e32834f04b6","volume":"30","author":"A Soro-Paavonen","year":"2012","unstructured":"Soro-Paavonen\u00a0A, Gordin\u00a0D, Forsblom\u00a0C et al (2012) Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. J\u00a0Hypertens 30:375\u2013383","journal-title":"J Hypertens"},{"key":"5168_CR15","unstructured":"ESC (2020) The European society for cardiology. ESC guidance for the diagnosis and management of CV disease during the COVID-19 pandemic. https:\/\/www.escardio.org\/Education\/COVID-19-and-Cardiology\/ESC-COVID-19-Guidance. Accessed 10 June 2020"},{"issue":"6","key":"5168_CR16","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/ehjcvp\/pvaa058","volume":"6","author":"SJ Pinto-Sietsma","year":"2020","unstructured":"Pinto-Sietsma\u00a0SJ, Flossdorf\u00a0M, Buchholz\u00a0VR et al (2020) Antihypertensive drugs in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother 6(6):415\u2013416","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"5168_CR17","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","volume":"382","author":"G Mancia","year":"2020","unstructured":"Mancia\u00a0G, Rea\u00a0F, Ludergnani\u00a0M et al (2020) Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N\u00a0Engl J Med 382:2431\u20132440","journal-title":"N Engl J Med"},{"key":"5168_CR18","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/jama.2020.11301","volume":"324","author":"EL Fosbol","year":"2020","unstructured":"Fosbol\u00a0EL, Butt\u00a0JH, Ostergaard\u00a0L et al (2020) Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA 324:168\u2013177","journal-title":"JAMA"},{"key":"5168_CR19","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1001\/jamacardio.2020.1855","volume":"5","author":"N Mehta","year":"2020","unstructured":"Mehta\u00a0N, Kalra\u00a0A, Nowacki\u00a0AS et al (2020) Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol 5:1020\u20131026","journal-title":"JAMA Cardiol"},{"key":"5168_CR20","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","volume":"382","author":"HR Reynolds","year":"2020","unstructured":"Reynolds\u00a0HR, Adhikari\u00a0S, Pulgarin\u00a0C et al (2020) Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N\u00a0Engl J Med 382:2441\u20132448","journal-title":"N Engl J Med"},{"key":"5168_CR21","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jinf.2020.05.052","volume":"81","author":"CJ Pirola","year":"2020","unstructured":"Pirola\u00a0CJ, Sookoian\u00a0S (2020) Estimation of renin-angiotensin-aldosterone-system (RAAS)-inhibitor effect on COVID-19 outcome: a meta-analysis. J\u00a0Infect 81:276\u2013281","journal-title":"J Infect"},{"key":"5168_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23421","author":"X Liu","year":"2020","unstructured":"Liu\u00a0X, Long\u00a0C, Xiong\u00a0Q et al (2020) Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis. Clin Cardiol. https:\/\/doi.org\/10.1002\/clc.23421","journal-title":"Clin Cardiol"},{"key":"5168_CR23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1001\/jama.2020.25864","volume":"325","author":"RD Lopes","year":"2021","unstructured":"Lopes\u00a0RD, Macedo\u00a0AVS, de Barros E Silva\u00a0PGM et al (2021) Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. JAMA 325:254\u2013264","journal-title":"JAMA"},{"key":"5168_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-2600(20)30558-0","volume":"9","author":"JB Cohen","year":"2021","unstructured":"Cohen\u00a0JB, Hanff\u00a0TC, William\u00a0P et al (2021) Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a\u00a0prospective, randomised, open-label trial. Lancet Respir Med 9:275\u2013284","journal-title":"Lancet Respir Med"},{"key":"5168_CR25","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S2213-2600(21)00214-9","volume":"9","author":"A Bauer","year":"2021","unstructured":"Bauer\u00a0A, Schreinlechner\u00a0M, Sappler\u00a0N et al (2021) Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a\u00a0prospective, parallel group, randomised, controlled, open-label trial. Lancet Respir Med 9:863\u2013872","journal-title":"Lancet Respir Med"},{"issue":"9","key":"5168_CR26","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.3390\/jcm11092580","volume":"11","author":"T Mazzoni","year":"2022","unstructured":"Mazzoni\u00a0T, Maraia\u00a0Z, Ruggeri\u00a0B et al (2022) Sartans and ACE inhibitors: mortality in patients hospitalized with COVID-19. Retrospective study in patients on long-term treatment who died in the Italian hospitals of area Vasta n.5-Marche region. J\u00a0Clin Med 11(9):2580. https:\/\/doi.org\/10.3390\/jcm11092580","journal-title":"J Clin Med"},{"key":"5168_CR27","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1161\/HYPERTENSIONAHA.114.03743","volume":"64","author":"MR Deshotels","year":"2014","unstructured":"Deshotels\u00a0MR, Xia\u00a0H, Sriramula\u00a0S et al (2014) Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism. Hypertension 64:1368\u20131375","journal-title":"Hypertension"},{"key":"5168_CR28","doi-asserted-by":"publisher","first-page":"390","DOI":"10.18433\/jpps31931","volume":"24","author":"R Nejat","year":"2021","unstructured":"Nejat\u00a0R, Sadr\u00a0AS, Freitas\u00a0B et al (2021) Losartan inhibits SARS-CoV\u20112 replication in vitro. J\u00a0Pharm Pharm Sci 24:390\u2013399","journal-title":"J Pharm Pharm Sci"},{"key":"5168_CR29","doi-asserted-by":"publisher","first-page":"100968","DOI":"10.1016\/j.conctc.2022.100968","volume":"29","author":"D Freilich","year":"2022","unstructured":"Freilich\u00a0D, Victory\u00a0J, Jenkins\u00a0P et al (2022) COVIDMED\u2014an early pandemic randomized clinical trial of losartan treatment for hospitalized COVID-19\u00a0patients. Contemp Clin Trials Commun 29:100968","journal-title":"Contemp Clin Trials Commun"},{"key":"5168_CR30","doi-asserted-by":"publisher","first-page":"100957","DOI":"10.1016\/j.eclinm.2021.100957","volume":"37","author":"MA Puskarich","year":"2021","unstructured":"Puskarich\u00a0MA, Cummins\u00a0NW, Ingraham\u00a0NE et al (2021) A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19. EClinicalMedicine 37:100957","journal-title":"EClinicalMedicine"},{"key":"5168_CR31","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40121-021-00453-3","volume":"10","author":"M Geriak","year":"2021","unstructured":"Geriak\u00a0M, Haddad\u00a0F, Kullar\u00a0R et al (2021) Randomized prospective open label study shows no impact on clinical outcome of adding losartan to hospitalized COVID-19 patients with mild hypoxemia. Infect Dis Ther 10:1323\u20131330","journal-title":"Infect Dis Ther"},{"key":"5168_CR32","doi-asserted-by":"publisher","first-page":"e14124","DOI":"10.1111\/ijcp.14124","volume":"75","author":"M Nouri-Vaskeh","year":"2021","unstructured":"Nouri-Vaskeh\u00a0M, Kalami\u00a0N, Zand\u00a0R et al (2021) Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: a randomised clinical trial. Int J Clin Pract 75:e14124","journal-title":"Int J Clin Pract"},{"key":"5168_CR33","doi-asserted-by":"publisher","first-page":"e222735","DOI":"10.1001\/jamanetworkopen.2022.2735","volume":"5","author":"MA Puskarich","year":"2022","unstructured":"Puskarich\u00a0MA, Ingraham\u00a0NE, Merck\u00a0LH et al (2022) Efficacy of losartan in hospitalized patients with COVID-19-induced lung injury: a randomized clinical trial. JAMA Netw Open 5:e222735","journal-title":"JAMA Netw Open"},{"key":"5168_CR34","doi-asserted-by":"publisher","first-page":"100962","DOI":"10.1016\/j.eclinm.2021.100962","volume":"37","author":"M Duarte","year":"2021","unstructured":"Duarte\u00a0M, Pelorosso\u00a0F, Nicolosi\u00a0LN et al (2021) Telmisartan for treatment of Covid-19\u00a0patients: an open multicenter randomized clinical trial. EClinicalMedicine 37:100962","journal-title":"EClinicalMedicine"},{"key":"5168_CR35","doi-asserted-by":"publisher","first-page":"e072175","DOI":"10.1136\/bmj-2022-072175","volume":"379","author":"MJ Jardine","year":"2022","unstructured":"Jardine\u00a0MJ, Kotwal\u00a0SS, Bassi\u00a0A et al (2022) Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial. BMJ 379:e72175","journal-title":"BMJ"},{"key":"5168_CR36","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1021\/acs.molpharmaceut.2c00448","volume":"20","author":"D Chen","year":"2023","unstructured":"Chen\u00a0D, Yun\u00a0X, Lee\u00a0D et al (2023) Telmisartan nanosuspension for inhaled therapy of COVID-19 lung disease and other respiratory infections. Mol Pharmaceutics 20:750\u2013757","journal-title":"Mol Pharmaceutics"},{"key":"5168_CR37","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","volume":"120","author":"A Oesterle","year":"2017","unstructured":"Oesterle\u00a0A, Laufs\u00a0U, Liao\u00a0JK (2017) Pleiotropic effects of statins on the cardiovascular system. Circ Res 120:229\u2013243","journal-title":"Circ Res"},{"key":"5168_CR38","doi-asserted-by":"publisher","first-page":"872370","DOI":"10.1155\/2014\/872370","volume":"2014","author":"P Mehrbod","year":"2014","unstructured":"Mehrbod\u00a0P, Omar\u00a0AR, Hair-Bejo\u00a0M et al (2014) Mechanisms of action and efficacy of statins against influenza. Biomed Res Int 2014:872370","journal-title":"Biomed Res Int"},{"key":"5168_CR39","doi-asserted-by":"publisher","first-page":"660490","DOI":"10.3389\/fphar.2021.660490","volume":"12","author":"SP Davies","year":"2021","unstructured":"Davies\u00a0SP, Mycroft-West\u00a0CJ, Pagani\u00a0I et al (2021) The hyperlipidaemic drug fenofibrate significantly reduces infection by SARS-coV\u20112 in cell culture models. Front Pharmacol 12:660490","journal-title":"Front Pharmacol"},{"key":"5168_CR40","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.jacc.2021.08.021","volume":"78","author":"AH Talasaz","year":"2021","unstructured":"Talasaz\u00a0AH, Sadeghipour\u00a0P, Aghakouchakzadeh\u00a0M et al (2021) Investigating lipid-modulating agents for prevention or treatment of COVID-19: JACC state-of-the-art review. J\u00a0Am Coll Cardiol 78:1635\u20131654","journal-title":"J Am Coll Cardiol"},{"key":"5168_CR41","first-page":"e068407","volume":"376","author":"I-S Investigators","year":"2022","unstructured":"Investigators\u00a0I\u2011S (2022) Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial. BMJ 376:e68407","journal-title":"BMJ"},{"key":"5168_CR42","doi-asserted-by":"publisher","first-page":"e0254635","DOI":"10.1371\/journal.pone.0254635","volume":"16","author":"LB Daniels","year":"2021","unstructured":"Daniels\u00a0LB, Ren\u00a0J, Kumar\u00a0K et al (2021) Relation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: findings from the American heart association\u2019s COVID-19 cardiovascular disease registry. PLoS ONE 16:e254635","journal-title":"PLoS ONE"},{"key":"5168_CR43","doi-asserted-by":"publisher","first-page":"R198","DOI":"10.1186\/cc9317","volume":"14","author":"M Noveanu","year":"2010","unstructured":"Noveanu\u00a0M, Breidthardt\u00a0T, Reichlin\u00a0T et al (2010) Effect of oral beta-blocker on short and long-term mortality in patients with acute respiratory failure: results from the BASEL-II-ICU study. Crit Care 14:R198","journal-title":"Crit Care"},{"key":"5168_CR44","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s13054-019-2562-y","volume":"23","author":"K Tan","year":"2019","unstructured":"Tan\u00a0K, Harazim\u00a0M, Tang\u00a0B et\u00a0al (2019) The association between premorbid beta blocker exposure and mortality in sepsis\u2014a systematic review. Crit Care 23:298","journal-title":"Crit Care"},{"key":"5168_CR45","doi-asserted-by":"publisher","first-page":"749291","DOI":"10.3389\/fimmu.2021.749291","volume":"12","author":"HM Al-Kuraishy","year":"2021","unstructured":"Al-Kuraishy\u00a0HM, Al-Gareeb\u00a0AI, Mostafa-Hedeab\u00a0G et al (2021) Effects of beta-blockers on the sympathetic and cytokines storms in Covid-19. Front Immunol 12:749291","journal-title":"Front Immunol"},{"key":"5168_CR46","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1182\/blood.2020007008","volume":"136","author":"EA Middleton","year":"2020","unstructured":"Middleton\u00a0EA, He\u00a0XY, Denorme\u00a0F et al (2020) Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 136:1169\u20131179","journal-title":"Blood"},{"key":"5168_CR47","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1093\/eurheartj\/ehaa733","volume":"41","author":"A Clemente-Moragon","year":"2020","unstructured":"Clemente-Moragon\u00a0A, Gomez\u00a0M, Villena-Gutierrez\u00a0R et al (2020) Metoprolol exerts a\u00a0non-class effect against ischaemia-reperfusion injury by abrogating exacerbated inflammation. Eur Heart\u00a0J 41:4425\u20134440","journal-title":"Eur Heart J"},{"key":"5168_CR48","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.jacc.2021.07.003","volume":"78","author":"A Clemente-Moragon","year":"2021","unstructured":"Clemente-Moragon\u00a0A, Martinez-Milla\u00a0J, Oliver\u00a0E et al (2021) Metoprolol in critically ill patients with COVID-19. J\u00a0Am Coll Cardiol 78:1001\u20131011","journal-title":"J Am Coll Cardiol"},{"key":"5168_CR49","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1111\/cts.13369","volume":"15","author":"K Matli","year":"2022","unstructured":"Matli\u00a0K, Al Kotob\u00a0A, Jamaleddine\u00a0W et al (2022) Managing endothelial dysfunction in COVID-19 with statins, beta blockers, nicorandil, and oral supplements: a pilot, double-blind, placebo-controlled, randomized clinical trial. Clin Transl Sci 15:2323\u20132330","journal-title":"Clin Transl Sci"},{"key":"5168_CR50","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1172\/JCI114924","volume":"86","author":"H Schunkert","year":"1990","unstructured":"Schunkert\u00a0H, Dzau\u00a0VJ, Tang\u00a0SS et\u00a0al (1990) Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. J\u00a0Clin Invest 86:1913\u20131920","journal-title":"J Clin Invest"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-023-05168-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-023-05168-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-023-05168-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T10:02:23Z","timestamp":1686736943000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-023-05168-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["5168"],"URL":"https:\/\/doi.org\/10.1007\/s00059-023-05168-4","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]},"assertion":[{"value":"24 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.\u00a0Dutsch and H.\u00a0Schunkert declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}